Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Jakafi in metastatic triple negative breast cancer
NCT03012230Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2017
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in triple negative breast cancer (TNBC), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 21 days and Incidence of Adverse Events. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03012230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012230.